{"classes":[{"categories":[{"measurements":[{"comment":"Criteria not met for CR or PR so DOR not calculated, data is not available.","groupId":"OG000","lowerLimit":"NA","upperLimit":"NA","value":"NA"},{"comment":"Criteria not met for CR or PR so DOR not calculated, data is not available.","groupId":"OG001","lowerLimit":"NA","upperLimit":"NA","value":"NA"},{"comment":"Criteria not met for CR or PR so DOR not calculated, data is not available.","groupId":"OG002","lowerLimit":"NA","upperLimit":"NA","value":"NA"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"3"},{"groupId":"OG001","value":"7"},{"groupId":"OG002","value":"11"}],"units":"Participants"}],"description":"The duration of overall response is measured from the time measurement criteria are met for CR or PR (whichever is first recorded) until the first date that recurrent or progressive disease is objectively documented (taking as reference for progressive disease the smallest measurements recorded since the treatment started). Progressive disease was measured by the Response Evaluation Criteria in Solid Tumors (RECIST) and is defined as at least a 20% increase in the sum of the diameters of target lesions, taking as reference the smallest sum on study. The appearance of one or more new lesions is also considered progressions.","dispersionType":"Full Range","groups":[{"description":"Dose Level 1: 170mcg LMB-100 given intravenously on days 1, 3 and 5 of a 21 day cycle for up to 4 cycles.","id":"OG000","title":"Dose Level 1: 170mcg LMB-100"},{"description":"Dose Level -1: 140mcg LMB-100 given intravenously on days 1, 3 and 5 of a 21 day cycle for up to 4 cycles.","id":"OG001","title":"Dose Level -1: 140mcg LMB-100"},{"description":"Dose Level -2: 100mcg LMB-100 + Nab-Paclitaxel given intravenously. LMB-100 given intravenously on days 1, 3 and 5 of a 21 day cycle for up to 2 cycles. Nab-Paclitaxel given intravenously on days 1 and 8 of each 21 day cycle for up to 6 cycles.","id":"OG002","title":"Dose Level -2: 100mcg LMB-100 + Nab-Paclitaxel"}],"paramType":"MEDIAN","reportingStatus":"POSTED","timeFrame":"time measurement criteria are met for CR or PR (whichever is first recorded) until the first date that recurrent or progressive disease is objectively documented by computed tomography (CT) scans performed every 6 weeks.","title":"Duration of Response (DOR)","type":"SECONDARY","unitOfMeasure":"months"}